Mucopolysaccharidosis Type VI clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • Adalimumab in MPS I, II, and VI

    Sorry, in progress, not accepting new patients

    Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

    Torrance, California

Our lead scientists for Mucopolysaccharidosis Type VI research studies include .

Last updated: